Scotia Capital’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Scotia Capital’s Portfolio TARO Stock Details TARO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,665	Closed	-$263K	–	778
2018 Q2	$263K	Hold	2,665	–	–	﹤0.01%	595
2018 Q1	$263K	Buy	2,665 +135	+5%	+$13.7K	﹤0.01%	622
2017 Q4	$265K	Buy	+2,530	New	+$278K	﹤0.01%	633
2013 Q4	–	Sell	-2,950	Closed	-$224K	–	567
2013 Q3	$224K	Buy	+2,950	New	+$191K	0.01%	446

Other funds holding TARO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return

FCH

Freestone Capital Holdings Seattle, Washington $3.3B AUM 21.14% 1-Year Est. Return

Scotia Capital's TARO Position: Q3 2018 in Review

Scotia Capital sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q3 2018, closing a stake of 2,665 shares — an estimated $263K sold.

Scotia Capital first reported a position in TARO in Q3 2013 and held it in 4 quarters. The position peaked at $265K in Q4 2017. 114 funds tracked by Wall St. Rank hold TARO as of Q3 2018.

Scotia Capital reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q3 2018 after selling out during the quarter.
Scotia Capital sold 2,665 Taro Pharmaceutical Industries Ltd. shares in Q3 2018, an estimated $263K.
Scotia Capital first reported a position in Taro Pharmaceutical Industries Ltd. in Q3 2013 and held it in 4 quarters.
Scotia Capital's Taro Pharmaceutical Industries Ltd. position peaked at $265K in Q4 2017.
114 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q3 2018.

Based on Scotia Capital's 13F filing for Q3 2018, filed 14 Nov 2018.